JP7796719B2 - 抗タウ抗体 - Google Patents

抗タウ抗体

Info

Publication number
JP7796719B2
JP7796719B2 JP2023501609A JP2023501609A JP7796719B2 JP 7796719 B2 JP7796719 B2 JP 7796719B2 JP 2023501609 A JP2023501609 A JP 2023501609A JP 2023501609 A JP2023501609 A JP 2023501609A JP 7796719 B2 JP7796719 B2 JP 7796719B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
set forth
sequence set
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533768A5 (https=
JP2023533768A (ja
Inventor
チャールズ ロバート ハリントン
ソーマン ソーミャ パリル
アンドリュー ジャスティン ラドクリフ ポーター
クロード ミシェル ウィシック
ムハンマド アラスト
ルイス カーク ペニー
リチャード ロフトハウス
Original Assignee
ジーティーインヴェント リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーティーインヴェント リミテッド filed Critical ジーティーインヴェント リミテッド
Publication of JP2023533768A publication Critical patent/JP2023533768A/ja
Publication of JP2023533768A5 publication Critical patent/JP2023533768A5/ja
Application granted granted Critical
Publication of JP7796719B2 publication Critical patent/JP7796719B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023501609A 2020-07-10 2021-07-09 抗タウ抗体 Active JP7796719B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
GB2010652.2 2020-07-10
PCT/EP2021/069160 WO2022008719A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies

Publications (3)

Publication Number Publication Date
JP2023533768A JP2023533768A (ja) 2023-08-04
JP2023533768A5 JP2023533768A5 (https=) 2024-05-09
JP7796719B2 true JP7796719B2 (ja) 2026-01-09

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501609A Active JP7796719B2 (ja) 2020-07-10 2021-07-09 抗タウ抗体

Country Status (10)

Country Link
US (1) US20230257452A1 (https=)
EP (1) EP4178980A1 (https=)
JP (1) JP7796719B2 (https=)
KR (1) KR20230038721A (https=)
CN (1) CN116194479A (https=)
AU (1) AU2021306653A1 (https=)
CA (1) CA3185175A1 (https=)
GB (1) GB202010652D0 (https=)
TW (1) TWI912331B (https=)
WO (1) WO2022008719A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250147051A1 (en) * 2022-01-12 2025-05-08 Gtinvent Limited Method for detecting a tau protein in a saliva sample
KR20240134175A (ko) * 2022-01-12 2024-09-06 지틴벤트 리미티드 샘플에서 타우(tau) 단백질 단편을 검출하기 위한 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504570A (ja) 2013-11-27 2017-02-09 アイピエリアン，インコーポレイティド タウオパチーの処置方法
JP2019525920A (ja) 2016-08-09 2019-09-12 イーライ リリー アンド カンパニー 併用療法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
WO2007110630A1 (en) 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
CA2896066C (en) * 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
UA128383C2 (uk) * 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
EP3601337A1 (en) * 2017-03-28 2020-02-05 Genentech, Inc. Methods of treating neurodegenerative diseases
US20250147051A1 (en) * 2022-01-12 2025-05-08 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504570A (ja) 2013-11-27 2017-02-09 アイピエリアン，インコーポレイティド タウオパチーの処置方法
JP2019525920A (ja) 2016-08-09 2019-09-12 イーライ リリー アンド カンパニー 併用療法

Also Published As

Publication number Publication date
AU2021306653A1 (en) 2023-03-02
US20230257452A1 (en) 2023-08-17
TW202214686A (zh) 2022-04-16
JP2023533768A (ja) 2023-08-04
EP4178980A1 (en) 2023-05-17
GB202010652D0 (en) 2020-08-26
KR20230038721A (ko) 2023-03-21
TWI912331B (zh) 2026-01-21
CA3185175A1 (en) 2022-01-13
WO2022008719A1 (en) 2022-01-13
CN116194479A (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
US7763249B2 (en) Human anti-amyloid β peptide antibody and fragment of said antibody
JP7722990B2 (ja) アミロイド沈着物を標的化するための修飾免疫グロブリン
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
BR112020018868A2 (pt) métodos baseados em anticorpo para detectar e tratar doença de alzheimer
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JP7796719B2 (ja) 抗タウ抗体
US12351623B2 (en) Antibody compositions targeting non-phosphorylated alpha-synuclein aggregates
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
GB2585252A (en) Tau epitope and binding molecules
JP2023531822A (ja) タウ結合分子
US20210139568A1 (en) Antibody-based methods of detecting and treating alzheimer's disease
RU2855123C1 (ru) Антитела против тау
US20250355001A1 (en) Method for detecting a tau protein fragment in a sample
WO2022060236A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251223

R150 Certificate of patent or registration of utility model

Ref document number: 7796719

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150